Best North America 3d Printed Drugs Market Tips You Will Read

North America has the largest share in the global 3D printed drugs market. 

The US is the only country that has approved the first 3D drug called  Spritam (levetiracetam) in the country. It is the first 3D-printed drug to receive approval from the U.S. The Food and Drug Administration (FDA) is now being shipped to pharmacies. The company is also working on at least three other 3D-printed drugs that it expects to eventually bring to market. Levetiracetam, the generic name for Spritam, has been available for the treatment of seizures for 15 years. But the new brand Spritam is the first to use the proprietary 3D-printing process to create a more dissolvable pill. The surge in demand for instantaneous soluble drugs that can disperse easily in the mouth is the major factor that drives the growth of the market in the country. Additionally, many state-of-the-art universities collaborate with 3D drug manufacturing companies for the research and development of new pharmaceuticals. 

For instance, in 2020, Aprecia Pharmaceuticals LLC, entered into a partnership with Purdue University’s College of Pharmacy, to bring advancement in technologies and science of 3D pharmaceutical printing. Through this partnership, the companies will focus on developing future 3D printed pharmaceutical equipment and medications.

According to a recent survey by PMLive, up to 50% of people have difficulties during pill intake. Some people find it difficult to swallow capsules due to their large sizes. Also, some heart patients feel difficulty swallowing the pills. 

According to the CDC, in 2015, 1.2% of the total US population had active epilepsy. This is about 3.4 million people with epilepsy nationwide, 3 million adults, and 470,000 children. Also, the latest estimates by the CDC, about 0.6% of children aged 0-17 years have active epilepsy. This factor has boosted the sale of 3D pharmaceuticals in the country.

In addition, technological advancement in the region, an increase in affordability, and a rise in awareness of 3D printing techniques fuel the market growth. Moreover, an increase in funds by government organizations to improve the healthcare infrastructure propels the growth of the 3D printed drugs market in the region.

However, adverse effects related to these drugs, high price, and single company monopoly not in the US and North America but the entire global market is hampering the growth of the market in the forecast period. Presently, all other companies which want to enter the market are performing research and development, some companies have their product in the pipeline. 

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com